DC4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring CGM DemandDexcom’s recurring-use sensor model can support durable revenue visibility because existing users regularly replace disposable sensors. That repeat demand, combined with multiple sales channels and reimbursement sources, can improve retention and reduce reliance on one-time device purchases.
Profitability And Cash GenerationStrong margins and substantial cash generation show meaningful operating leverage as Dexcom scales. The combination of improving profitability, high cash conversion in dollars, and reduced leverage gives the company resources to fund product investment, capacity expansion, and shareholder returns.
Product Adoption And Reimbursement ExpansionBroader payer coverage expands the addressable reimbursed population, while G7 conversion supports adoption within the installed base. Together, reimbursement progress and product migration can strengthen utilization, retention, and Dexcom’s position in CGM over the next several quarters.
Bears Say
Revenue Growth DecelerationThe sharp slowdown in trailing revenue growth raises a durable execution concern because future earnings expansion depends on restoring stronger demand. If slower growth persists, it could limit operating leverage, reduce reinvestment capacity, and make margin progress harder to sustain.
Manufacturing Ramp And Quality Execution RiskCapacity expansion should support long-term scale, but the Ireland ramp introduces near-term operating costs and execution demands. Dexcom must also maintain product quality while scaling, because renewed failures or launch disruption could affect customer trust, warranty costs, and adoption.
Medicare Coverage UncertaintyMedicare coverage could materially broaden CGM access, but uncertain timing and conditions make that opportunity less dependable over the planning horizon. Delays or restrictive terms could defer patient additions, reimbursement benefits, and the expected contribution from the older or broader diabetes population.
Dexcom News
DC4 FAQ
What was Dexcom’s price range in the past 12 months?
Currently, no data Available
What is Dexcom’s market cap?
Dexcom’s market cap is CHF27.88B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 22, 2026 which is in 27 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 30, 2026. The company reported CHF0.566 earnings per share for the quarter, beating the consensus estimate of CHF0.494 by CHF0.072.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.54.
How many shares outstanding does Dexcom have?
Currently, no data Available
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of CHF0.566 in its last earnings report, beating expectations of CHF0.494. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in CH:DC4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF77.01 (― Upside)
CHF77.01 (― Upside)
Blogger Sentiment
Bullish
CH:DC4 Sentiment 73%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DC4 Company Deck
DC4 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial message: double-digit revenue growth, substantial margin expansion (400 bps YoY), strong cash generation, successful product rollouts and encouraging clinical data (CONNECT) that is driving payer coverage momentum. Near-term headwinds include FX impact, Ireland manufacturing ramp costs, tougher international comps in the back half, and remaining uncertainties around Medicare coverage terms and timing. Overall, achievements and momentum on growth, margins, cash flow, product adoption and clinical evidence substantially outweigh the manageable near-term challenges.View all CH:DC4 earnings summariesDC4 Revenue Breakdown
71.53% U.S.
28.47% International
DC4 Stock 12 Month Forecast
Average Price Target
―Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―